heavy selling premarket. already 3.60. this could be an ugly day again for this major disappointment. please fire Jacob and sell the company. do the right thing.
no point of complaining about sgyp. we all were duped into thinking this was a winner. when you put your trust in the wrong CEO it is what it is. he collects his big check undeservingly and good for him. he ruined it for shareholders . nobody on the management team buys any out of there own pocket. man I wish we had an ethical CEO who sold or partnered with big pharma. live and learn.
There's a spreadsheet going around with the Trulance numbers, 809 RX for week of 5/19. This sheet was created by longs that have access to the Bloomberg Terminal, and is in fact, 100% accurate per IMS methodology. This was less than a 2% weekly growth for Trulance, you are now seeing #fakenews responses from loyal "old longs" that can't come to grips with this failed launch. I told everyone last year this launch would be a disaster using rent a reps from Publicis, and that has now become reality. Big Pharma marketing machine is only way Trulance can be saved, and something must be done soon. Launch trajectory shapes the life and peak sales of the drug. This $12-15 BO has continued to stay the course of CITI's PT. I predict PPS will slide a bit more. CITI will then upgrade to eventual BO PPS of 6.50-7, which will be a great premium for those of us that are about to go long on this!
can somebody explain why 4 executive of the company that not yet making money are getting paid so handsomely. i think bigger portion of their compensation should be paid in shares. They have no interest in building shareholder's value. No wonder they are not looking to sell the company, they will milk it to the ground
Name Title Pay Exercised Age Dr. Gary S. Jacob Ph.D. Chairman, CEO 844.01k Dr. Kunwar Shailubhai Chief Scientific Officer 524.29k Dr. Patrick H. Griffin Chief Medical Officer 607.65k Mr. Troy Hamilton Chief Commercial Officer 567.5k Mr. Bernard F. Denoyer Exec. Officer 331.19k
shorts, bears and M/M holding hands giggling and acting giddy as they observe the PPS drop in SGYP....hurrah they say...jobs lost and product's squashed..we win!!!!.....did you????
You'd have to be a fool to hold this stock and have faith in this horrific management team!
2 bucks per share coming soon...
John-you've been silent on this lately. I stand my previous assertion, and CITI PT, that SGYP will become a "buy" once it drops below $3.50 PPS. Do you believe the notion, the the cult long base claims, this is all a "retail wash"? The MM's are essentially "taking" the retail shares at these low low prices, so they can then facilitate the much anticipation juicy buyout scenario, no? Every "long" comment I read echo's the sentiments of "SirFrederick" saying #nevergetmyshares, so I'm wondering how exactly then are the MM's stealing the "retail" shares if no one is giving them away to them?
Jacob you are truly an a hole for what you have done on this launch. you went it alone and screwed it up. resign already and let the honest people get rewarded.
I wouldn't trade another share of this turd till after dilution around 3 or 3.25 a share. have patience
Rough Picture: USA Lowered Revenue Projection: $30M 2017, $140M 2018, $250M in 2019 and $350M in 2020 2018 should be a breakout year for Trulance because of the substantially improved coverage, the approval in IBS-C in Q1 and the launch in that indication and the company being in a stronger financial position with growing net sales which it can plow back to sales and marketing to accelerate prescription growth. I continue to believe that Trulance has blockbuster potential, even in Synergy's hands. My expectations for Trulance are lower compared to Linzess because Linzess was approved for both CIC and IBS-C while Trulance only has CIC in its label for now. The other reason is Allergan being much stronger commercially with more feet on the ground and more capital allocated to sales and marketing. 2018 should be a breakout year for Trulance because of the substantially improved coverage, the approval in IBS-C in Q1 and the launch in that indication and the company being in a stronger financial position with growing net sales which it can plow back to sales and marketing to accelerate prescription growth. I continue to believe that Trulance has blockbuster potential, even in Synergy's hands.
Cash in hand at end of Qtr 1 =$139M, Burn rate =$60M/Qtr, need to reduce burn rate to $55M/Qtr. Need $220M/year to operate.
Assuming they achieve lowered revenue projections above, they will need to raise at least $150M to reach profitability by 2019 end.
If they dilute today, they can generate >$150M with 50M shares.
Assuming 275M float by 2019, expect share price at $5-6/share in 2 years (based on rough valuation at multiple of 4 x $350M Revenue projection in 2020)
Recommendation: Buy under $3.50 post second round of dilution
Factors that can positively tip the balance: Partner for worldwide sales (except USA), Buy-out in 1 year
Can a drug company use direct mail to physicians to market their product ? There aren't that many GI board certified docs in USA, maybe 15,000. If doable, why not send all a letter showing Tru advantages, and follow ups every 2-3 months showing adoption (prayerfully) ? If 2% successful, that's 300 scrips. Calling all marketing geniuses here. Bring your ideas, send them to management. Our company couldn't sell water in the Sahara. Helllllllllllllp !!!!!
What do you know, short interest dropped by 14,132,134 shares to the lowest since mid march. Sure would like a positive surprise to hit to fuel a squeeze.
Disgraceful...How could 50 salespeople produce just 15 sales ?. .Disgusting...Fire them all and get a partner....Half a loaf of something is better than a full loaf of nothing...Jacobs, this failure is on you...It's time for a change
Helen Keller would make a better CEO
This MF stock is down everyday, I'm going to sell all my shares.
The sales will come. Trulance is the superior option over current meds. The docs will be doing there patients a disservice by not recommending it over Linzess.
Funny how the pumpers are silent now.....More pain to come.....Dilution is imminent. $3/share x 250M shares (post dilution) = $750M valuation is a natural target now. As cash burn proceeds with ferocity (>$50M/Qtr) with marginal sales, look out for even further lows. Buy-out being facilitated around $6-7/share.
I have a great idea. There is only 225 million shares outstanding. let's get together and buy the remaining shares. Then fire whomever.
This is getting so hokie we might as well square dance around the hills of WVA with one shoe off.